108 related articles for article (PubMed ID: 20384590)
1. Intraocular inflammation after intravitreal ranibizumab injections.
Fauser S; Schroeder S; Caramoy A; Kirchhof B; Lappas A
Acta Ophthalmol; 2011 Feb; 89(1):e98-9. PubMed ID: 20384590
[No Abstract] [Full Text] [Related]
2. Ranibizumab and stroke.
Ueta T; Yanagi Y; Tamaki Y; Yamaguchi T
Ophthalmology; 2010 Sep; 117(9):1860; author reply 1860-1. PubMed ID: 20816253
[No Abstract] [Full Text] [Related]
3. Outcomes and risk factors associated with endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents.
Shah CP; Garg SJ; Vander JF; Brown GC; Kaiser RS; Haller JA;
Ophthalmology; 2011 Oct; 118(10):2028-34. PubMed ID: 21705087
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of safety for bilateral same-day intravitreal injections of antivascular endothelial growth factor therapy.
Lima LH; Zweifel SA; Engelbert M; Sorenson JA; Slakter JS; Cooney MJ; Klancnik JM; Yannuzzi LA; Freund KB
Retina; 2009 Oct; 29(9):1213-7. PubMed ID: 19934815
[TBL] [Abstract][Full Text] [Related]
5. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration.
Boyer DS; Heier JS; Brown DM; Francom SF; Ianchulev T; Rubio RG
Ophthalmology; 2009 Sep; 116(9):1731-9. PubMed ID: 19643495
[TBL] [Abstract][Full Text] [Related]
6. A 1-year retrospective review of ranibizumab for naive nonsubfoveal choroidal neovascularization secondary to age-related macular degeneration.
Arias L; Ruiz-Moreno JM; Gómez-Ulla F; Fernández M; Montero J
Retina; 2009; 29(10):1444-9. PubMed ID: 19730163
[TBL] [Abstract][Full Text] [Related]
7. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study.
Lalwani GA; Rosenfeld PJ; Fung AE; Dubovy SR; Michels S; Feuer W; Davis JL; Flynn HW; Esquiabro M
Am J Ophthalmol; 2009 Jul; 148(1):43-58.e1. PubMed ID: 19376495
[TBL] [Abstract][Full Text] [Related]
8. Re: Infectious endophthalmitis after intravitreal injection of antiangiogenic agents.
Ranchod TM; Leverenz VR; Chintala SK; Cheng M; Trese MT; Giblin FJ
Retina; 2010; 30(10):1752-4; author reply 1754. PubMed ID: 21060278
[No Abstract] [Full Text] [Related]
9. Endophthalmitis after anti-VEGF injections.
Klein KS; Walsh MK; Hassan TS; Halperin LS; Castellarin AA; Roth D; Driscoll S; Prenner JL
Ophthalmology; 2009 Jun; 116(6):1225.e1. PubMed ID: 19486799
[No Abstract] [Full Text] [Related]
10. Case of anterior uveitis after intravitreal injection of bevacizumab.
Pieramici DJ; Avery RL; Castellarin AA; Nasir MA; Rabena M
Retina; 2006 Sep; 26(7):841-2. PubMed ID: 16963867
[No Abstract] [Full Text] [Related]
11. Vitreous web after pars plana vitrectomy and bevacizumab with fluid-air exchange.
Chiang A; Reddy S; Tsui I; Hubschman JP
Semin Ophthalmol; 2011 Jan; 26(1):25-7. PubMed ID: 21275601
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration.
Dadgostar H; Ventura AA; Chung JY; Sharma S; Kaiser PK
Ophthalmology; 2009 Sep; 116(9):1740-7. PubMed ID: 19643484
[TBL] [Abstract][Full Text] [Related]
13. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration.
Rosenfeld PJ; Schwartz SD; Blumenkranz MS; Miller JW; Haller JA; Reimann JD; Greene WL; Shams N
Ophthalmology; 2005 Jun; 112(6):1048-53. PubMed ID: 15885778
[TBL] [Abstract][Full Text] [Related]
14. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.
Funk M; Karl D; Georgopoulos M; Benesch T; Sacu S; Polak K; Zlabinger GJ; Schmidt-Erfurth U
Ophthalmology; 2009 Dec; 116(12):2393-9. PubMed ID: 19815292
[TBL] [Abstract][Full Text] [Related]
15. Acute endophthalmitis following intravitreal bevacizumab (Avastin) injection.
Aggio FB; Farah ME; de Melo GB; d'Azevedo PA; Pignatari AC; Höfling-Lima AL
Eye (Lond); 2007 Mar; 21(3):408-9. PubMed ID: 17277758
[TBL] [Abstract][Full Text] [Related]
16. Retinal pigment epithelial tear after intravitreal ranibizumab.
Bakri SJ; Kitzmann AS
Am J Ophthalmol; 2007 Mar; 143(3):505-7. PubMed ID: 17317396
[TBL] [Abstract][Full Text] [Related]
17. Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion.
Spaide RF; Chang LK; Klancnik JM; Yannuzzi LA; Sorenson J; Slakter JS; Freund KB; Klein R
Am J Ophthalmol; 2009 Feb; 147(2):298-306. PubMed ID: 18929354
[TBL] [Abstract][Full Text] [Related]
18. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.
Fung AE; Lalwani GA; Rosenfeld PJ; Dubovy SR; Michels S; Feuer WJ; Puliafito CA; Davis JL; Flynn HW; Esquiabro M
Am J Ophthalmol; 2007 Apr; 143(4):566-83. PubMed ID: 17386270
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal ranibizumab may induce retinal arteriolar vasoconstriction in patients with neovascular age-related macular degeneration.
Papadopoulou DN; Mendrinos E; Mangioris G; Donati G; Pournaras CJ
Ophthalmology; 2009 Sep; 116(9):1755-61. PubMed ID: 19560206
[TBL] [Abstract][Full Text] [Related]
20. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study.
Heier JS; Antoszyk AN; Pavan PR; Leff SR; Rosenfeld PJ; Ciulla TA; Dreyer RF; Gentile RC; Sy JP; Hantsbarger G; Shams N
Ophthalmology; 2006 Apr; 113(4):633.e1-4. PubMed ID: 16483659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
